Loading clinical trials...
Loading clinical trials...
A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With Larazotide Acetate (AT-1001)
Conditions
Interventions
larazotide acetate
placebo
Locations
33
United States
Study Site
Orange, California, United States
Study Site
San Francisco, California, United States
Study Site
Torrington, Connecticut, United States
Study Site
Jacksonville, Florida, United States
Study Site
Topeka, Kansas, United States
Study Site
Lexington, Kentucky, United States
Start Date
February 1, 2008
Primary Completion Date
July 1, 2009
Completion Date
December 1, 2009
Last Updated
September 20, 2017
NCT07239336
NCT07039773
NCT06356220
NCT07069127
NCT04806620
NCT07177287
Lead Sponsor
9 Meters Biopharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions